新发低体积转移性前列腺癌的前列腺及转移灶定向放疗
该回顾性研究纳入21例新发低体积转移性前列腺癌患者,在全身治疗基础上接受前列腺定向放疗联合转移灶定向放疗。放疗耐受良好,无≥III级胃肠或泌尿毒性,67%患者PSA不可测,14%在放疗后40个月内出现生化复发。结论认为该联合方案可行且生化控制前景良好。
要点
- 联合放疗耐受良好,无≥III级胃肠或泌尿毒性。
- 放疗后67%患者PSA不可测,14%在40个月内生化复发。
- 需前瞻性大样本研究明确获益亚组。
核心结论
- 新发低体积转移性前列腺癌在标准治疗基础上联合前列腺定向放疗和转移灶定向放疗可行、耐受良好,并伴随有前景的生化控制。
研究设计与样本
- 回顾性分析2018至2025年间21例新发低体积转移性前列腺癌患者,接受前列腺定向放疗联合转移灶定向放疗及全身治疗。
- 分期采用PSMA-PET/CT成像(21例中19例)。
- 放疗包括高剂量外照射前列腺定向放疗和针对所有可检测骨及淋巴结转移的转移灶定向放疗。
- 毒性采用CTCAE v5.0、IPSS和EPIC-26问卷评估。
主要发现
- 所有肿瘤部位追加放疗耐受良好,未发生≥III级胃肠或泌尿毒性。
- 最常见不良事件与激素治疗相关。
- 泌尿和肠道领域生活质量保持稳定或改善。
- 全身治疗基础上放疗后67%患者达到PSA不可测。
- 放疗完成后40个月内14%患者出现生化复发。
关键数值与推荐
- 67%患者放疗后PSA不可测。
- 14%患者在放疗完成后40个月内生化复发。
- 未发生≥III级胃肠或泌尿毒性。
临床怎么用
- 对新发低体积转移性前列腺癌患者,可考虑在全身治疗基础上联合前列腺定向放疗和转移灶定向放疗。
- 治疗时应关注激素治疗相关不良事件,并监测泌尿、肠道生活质量。
局限性
- 回顾性设计,样本量仅21例。
- 需前瞻性更大样本研究整合PSMA-PET/CT及其他风险分层因素,以明确最获益亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of radiotherapy in de novo low-volume metastatic prostate cancer (LVmPC) is constantly evolving and still offers considerable potential for further optimization. Rising interest in this topic demands further investigations in this specific patient cohort. We report on clinical outcomes and toxicity of combined prostate-directed (PDRT) and metastasis-directed radiotherapy (MDRT) with ablative dose concepts in patients with de novo LVmPC. METHODS: We retrospectively analyzed 21 patients with LVmPC treated with PDRT plus MDRT between 2018 and 2025 in addition to systemic treatment. Staging was performed with PSMA-PET/CT imaging (n = 19/21). Radiotherapy included high-dose external beam PDRT and MDRT to all detectable bone and nodal metastases. Toxicity was assessed using CTCAE v5.0, IPSS, and EPIC-26 questionnaires. Oncologic outcomes included biochemical recurrence-free survival, PSA response, and time to next-line systemic therapy. RESULTS: Additional radiotherapy of all tumor sites in LVmPC was well tolerated; no grade ≥ III gastrointestinal or genitourinary toxicity occurred. The most common adverse events were associated with hormonal therapy. Quality of life remained stable or improved in urinary and bowel domains. Undetectable PSA was achieved in 67 % of patients after radiotherapy in addition to systemic therapy. 14 % of the patients developed biochemical recurrence within 40 months after radiotherapy completion. CONCLUSION: Combined PDRT and MDRT in addition to standard of care in patients with de novo LVmPC is feasible, well tolerated, and associated with promising biochemical control. Further prospective studies with larger patient cohorts integrating PSMA-PET/CT and other risk stratification factors are warranted to better define which patient subgroups benefit most from additional radiotherapy.
引用
- Bolten JH, Weykamp F, Grott C, et al. Prostate- and metastases-directed radiotherapy in de novo low-volume metastatic prostate cancer. Clin Transl Radiat Oncol. 2025. PMID: 41334109. doi:10.1016/j.ctro.2025.101072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。